Statin‐associated myopathy

By I. Hamilton‐Craig. Medical Journal of Australia, 2001

758 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/d579758cab67822f7a10f13a23669ce04f003447

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Emergency Medicine

In Surgery

P. Marik

Citations in the corpus

Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning (2007, background): “…study, ischemia/reperfusion resulted in a deterioration of cardiac contractile function in isolated hearts of rabbits fed a 2% cholesterol-enriched diet for 2 to 3 weeks compared with rabbits fed the same diet for a longer duration (5–16 weeks) or rabbits fed a normal diet (Tilton et al., 1987).”
Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake (2011, background): “…include a high statin dose, drug-drug interactions (especially those that raise statin plasma concentrations ), very high age, existence of multiple concomitant diseases, hypothyroidism, and certain inherited muscle disorders (Thompson et al., 2003; Neuvonen et al., 2006; Ghatak et al., 2010).”
Bench-to-bedside review: Rhabdomyolysis – an overview for clinicians (2004, background): “Risk factors for the development of a statin-induced myopathy include high dosages, increasing age, female sex, renal and hepatic insufficiency, diabetes mellitus and concomitant therapy with drugs such as fibrates, cyclosporine, macrolide antibiotics, warfarin and digoxin [61].”
Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study (2005, result): “In the PRIMO study population, 10.5% of patients on high-dosage statin therapy complained of muscle pain, a figure which is considerably higher than that reported previously for clinical trials [ 24 ].”